Valuation: Crinetics Pharmaceuticals, Inc.

Market Cap 8.84B 7.77B 7.25B 6.66B 12.46B 847B 12.77B 86.02B 33.64B 419B 33.21B 32.49B 1,449B P/E 2026 *
-17.8x
P/E 2027 * -20.1x
Enterprise Value 7.81B 6.86B 6.41B 5.88B 11B 748B 11.28B 75.95B 29.7B 370B 29.32B 28.68B 1,280B EV / Sales 2026 *
114x
EV / Sales 2027 * 46.3x
Free-Float
98.21%
Yield 2026 *
-
Yield 2027 * -
1 day+0.02%
1 week+0.19%
Current month+124.16%
1 month+127.07%
3 months+118.21%
6 months+61.68%
Current year+80.19%
1 week 83.67
Extreme 83.67
84
1 month 37.36
Extreme 37.365
84
Current year 32.3
Extreme 32.3
84
1 year 25.83
Extreme 25.83
84
3 years 15.76
Extreme 15.76
84
5 years 15.23
Extreme 15.23
84
10 years 10.63
Extreme 10.63
84
Manager TitleAgeSince
Chief Executive Officer 64 2008-11-30
Chief Tech/Sci/R&D Officer 60 2021-09-30
Director of Finance/CFO 51 2025-02-27
Director TitleAgeSince
Chairman 78 2015-09-30
Director/Board Member 64 2008-10-31
Director/Board Member 61 2018-01-31
Date Insider Type Main position Quantity % Market Cap.
7/2/26 Sell

Director

-3,000 0.0028%
6/18/26 Free

Chairman

15,655 0.0148%
6/18/26 Free

Director

15,655 0.0148%
Change 5-day change 1-year change 3-year change Capi.($)
+0.02%+0.19%+186.57%+346.41% 8.84B
-1.68%-4.37%+45.68%+66.78% 55.2B
+2.83%+0.48%+28.18%+82.59% 55.6B
+0.54%+1.22%-16.62%-13.47% 23.51B
-0.97%-3.30%-1.79%+383.00% 22.35B
-4.01%-3.67%+13.17%-14.29% 20.6B
-0.82%-2.60%+26.72%-33.46% 17.45B
-3.34%-7.77%+23.78%+536.66% 15.16B
-2.09%+0.64%+49.78%+178.74% 13.91B
-3.14%-8.47%+165.37%+292.18% 13.74B
Average -1.27%-1.13%+52.08%+182.51% 24.64B
Weighted average by Cap. -0.67%-0.49%+38.03%+135.35%

Financials

2026 *2027 *
Net sales 68.49M 60.18M 56.18M 51.56M 96.51M 6.56B 98.89M 666M 261M 3.25B 257M 252M 11.22B 172M 151M 141M 130M 243M 16.49B 249M 1.67B 655M 8.16B 646M 632M 28.21B
Net income -516M -454M -424M -389M -728M -49.47B -746M -5.02B -1.96B -24.48B -1.94B -1.9B -84.63B -473M -415M -388M -356M -666M -45.27B -682M -4.6B -1.8B -22.4B -1.77B -1.74B -77.43B
Net Debt -1.04B -910M -849M -779M -1.46B -99.14B -1.49B -10.07B -3.94B -49.06B -3.89B -3.8B -170B -865M -760M -710M -651M -1.22B -82.87B -1.25B -8.41B -3.29B -41.01B -3.25B -3.18B -142B
Logo Crinetics Pharmaceuticals, Inc.
Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead development candidate, PALSONIFY (paltusotine), is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Its second product candidate is Atumelnant, which is in clinical development for congenital adrenal hyperplasia (CAH) and patients with either Cushing's disease or Ectopic ACTH Syndrome (EAS). Its drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including other programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, diabetes and obesity.
Employees
594
Date Price Change Volume
26-07-29 US$83.88 +0.02% 1,621,555
26-07-28 US$83.86 +0.01% 2,316,639
26-07-27 US$83.85 +0.14% 5,216,887
26-07-24 US$83.73 +0.10% 2,344,336
26-07-23 US$83.65 -0.08% 4,268,877
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
14
Last Close Price
83.88USD
Average target price
85.50USD
Spread / Average Target
+1.93%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CRNX Stock